Gland Pharma Limited IPO
Gland Pharma Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹1,490–₹1,500 per share to raise ₹6,480 crore. The issue was subscribed 2.06× overall (QIBs 6.4×, NIIs 0.51×, retail 0.24×). It listed on 20 Nov 2020 at ₹1,710 and closed its first day at ₹1,820, a listing gain of +21.3% versus the ₹1,500 issue price. It now trades around ₹3,096 (+106.4% versus the issue price).
Frequently asked questions
- How many times was the Gland Pharma Limited IPO subscribed?
- The Gland Pharma Limited IPO was subscribed 2.06× overall — 6.4× in the QIB category, 0.51× among non-institutional investors, 0.24× in retail.
- What were the Gland Pharma Limited IPO listing gains?
- Gland Pharma Limited listed on 20 Nov 2020 at ₹1,710, closing its first day at ₹1,820 — a listing gain of +21.3% versus the ₹1,500 issue price.
- What were the retail allotment odds for the Gland Pharma Limited IPO?
- Retail was subscribed 0.24×, so a single-lot application had roughly a 100% chance of allotment — most applicants were allotted, and allotment was finalised on 16 Nov 2020.
- What was the price band and lot size of the Gland Pharma Limited IPO?
- The price band was ₹1,490–₹1,500 per share, with a minimum lot of 10 shares (₹15,000 at the upper band).
- Who were the registrar and lead manager for the Gland Pharma Limited IPO?
- Link Intime India Private Limited was the registrar, and Kotak Mahindra Capital was the book-running lead manager.